Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy

Daniel A Sussman, Erika Escalona-Benz, Matthew S. Benz, Brandy C. Hayden, William J Feuer, Nicole Cicciarelli, Stuart Toledano, Arnold Markoe, Timothy G. Murray

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objective: To determine the time course and extent of tumor reduction associated with systemic chemotherapy or external beam radiotherapy (EBRT) in the treatment of advanced intraocular retinoblastoma. Methods: Retrospective review of children with Reese-Ellsworth stages IV and V retinoblastoma undergoing primary globe-conserving therapy with either systemic chemoreduction or EBRT. Study variables were recorded at baseline, at monthly intervals for the first 6 months, and at 12 months after the initiation of treatment. Tumor volumes were calculated using basal area and height values determined by ultrasonography, physical examination, and fundus photographic review. Main Outcome Measures: Outcome measures included tumor volume, tumor reduction, regression pattern, treatment-related complications, metastases, and survival. Results: Twenty-six eyes of 26 patients were evaluated for tumor response; 18 patients were treated with systemic chemotherapy and 8 patients were treated with EBRT. Median follow-up was 36 months. A mean 68% reduction in tumor volume occurred after 1 cycle of chemotherapy compared with a 12% reduction at a similar time point (1 month) after initiation of EBRT (P<.004). There was no statistically significant difference in tumor volume reduction between treatment modalities at the 12-month follow-up visit. Both systemic chemoreduction and EBRT achieved 100% globe conservation and 100% patient survival in this series. Conclusions: Retinoblastoma reduction exhibits a differential time course based on the applied primary treatment. Systemic chemotherapy is associated with earlier tumor reduction than EBRT.

Original languageEnglish
Pages (from-to)979-984
Number of pages6
JournalArchives of Ophthalmology
Volume121
Issue number7
DOIs
StatePublished - Jul 1 2003

Fingerprint

Retinoblastoma
Radiotherapy
Tumor Burden
Drug Therapy
Neoplasms
Therapeutics
Outcome Assessment (Health Care)
Survival
Physical Examination
Ultrasonography
Neoplasm Metastasis

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Sussman, D. A., Escalona-Benz, E., Benz, M. S., Hayden, B. C., Feuer, W. J., Cicciarelli, N., ... Murray, T. G. (2003). Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy. Archives of Ophthalmology, 121(7), 979-984. https://doi.org/10.1001/archopht.121.7.979

Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy. / Sussman, Daniel A; Escalona-Benz, Erika; Benz, Matthew S.; Hayden, Brandy C.; Feuer, William J; Cicciarelli, Nicole; Toledano, Stuart; Markoe, Arnold; Murray, Timothy G.

In: Archives of Ophthalmology, Vol. 121, No. 7, 01.07.2003, p. 979-984.

Research output: Contribution to journalArticle

Sussman, DA, Escalona-Benz, E, Benz, MS, Hayden, BC, Feuer, WJ, Cicciarelli, N, Toledano, S, Markoe, A & Murray, TG 2003, 'Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy', Archives of Ophthalmology, vol. 121, no. 7, pp. 979-984. https://doi.org/10.1001/archopht.121.7.979
Sussman, Daniel A ; Escalona-Benz, Erika ; Benz, Matthew S. ; Hayden, Brandy C. ; Feuer, William J ; Cicciarelli, Nicole ; Toledano, Stuart ; Markoe, Arnold ; Murray, Timothy G. / Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy. In: Archives of Ophthalmology. 2003 ; Vol. 121, No. 7. pp. 979-984.
@article{35ae40e7a304455188db8f4c5bfdcf16,
title = "Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy",
abstract = "Objective: To determine the time course and extent of tumor reduction associated with systemic chemotherapy or external beam radiotherapy (EBRT) in the treatment of advanced intraocular retinoblastoma. Methods: Retrospective review of children with Reese-Ellsworth stages IV and V retinoblastoma undergoing primary globe-conserving therapy with either systemic chemoreduction or EBRT. Study variables were recorded at baseline, at monthly intervals for the first 6 months, and at 12 months after the initiation of treatment. Tumor volumes were calculated using basal area and height values determined by ultrasonography, physical examination, and fundus photographic review. Main Outcome Measures: Outcome measures included tumor volume, tumor reduction, regression pattern, treatment-related complications, metastases, and survival. Results: Twenty-six eyes of 26 patients were evaluated for tumor response; 18 patients were treated with systemic chemotherapy and 8 patients were treated with EBRT. Median follow-up was 36 months. A mean 68{\%} reduction in tumor volume occurred after 1 cycle of chemotherapy compared with a 12{\%} reduction at a similar time point (1 month) after initiation of EBRT (P<.004). There was no statistically significant difference in tumor volume reduction between treatment modalities at the 12-month follow-up visit. Both systemic chemoreduction and EBRT achieved 100{\%} globe conservation and 100{\%} patient survival in this series. Conclusions: Retinoblastoma reduction exhibits a differential time course based on the applied primary treatment. Systemic chemotherapy is associated with earlier tumor reduction than EBRT.",
author = "Sussman, {Daniel A} and Erika Escalona-Benz and Benz, {Matthew S.} and Hayden, {Brandy C.} and Feuer, {William J} and Nicole Cicciarelli and Stuart Toledano and Arnold Markoe and Murray, {Timothy G.}",
year = "2003",
month = "7",
day = "1",
doi = "10.1001/archopht.121.7.979",
language = "English",
volume = "121",
pages = "979--984",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "7",

}

TY - JOUR

T1 - Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy

AU - Sussman, Daniel A

AU - Escalona-Benz, Erika

AU - Benz, Matthew S.

AU - Hayden, Brandy C.

AU - Feuer, William J

AU - Cicciarelli, Nicole

AU - Toledano, Stuart

AU - Markoe, Arnold

AU - Murray, Timothy G.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Objective: To determine the time course and extent of tumor reduction associated with systemic chemotherapy or external beam radiotherapy (EBRT) in the treatment of advanced intraocular retinoblastoma. Methods: Retrospective review of children with Reese-Ellsworth stages IV and V retinoblastoma undergoing primary globe-conserving therapy with either systemic chemoreduction or EBRT. Study variables were recorded at baseline, at monthly intervals for the first 6 months, and at 12 months after the initiation of treatment. Tumor volumes were calculated using basal area and height values determined by ultrasonography, physical examination, and fundus photographic review. Main Outcome Measures: Outcome measures included tumor volume, tumor reduction, regression pattern, treatment-related complications, metastases, and survival. Results: Twenty-six eyes of 26 patients were evaluated for tumor response; 18 patients were treated with systemic chemotherapy and 8 patients were treated with EBRT. Median follow-up was 36 months. A mean 68% reduction in tumor volume occurred after 1 cycle of chemotherapy compared with a 12% reduction at a similar time point (1 month) after initiation of EBRT (P<.004). There was no statistically significant difference in tumor volume reduction between treatment modalities at the 12-month follow-up visit. Both systemic chemoreduction and EBRT achieved 100% globe conservation and 100% patient survival in this series. Conclusions: Retinoblastoma reduction exhibits a differential time course based on the applied primary treatment. Systemic chemotherapy is associated with earlier tumor reduction than EBRT.

AB - Objective: To determine the time course and extent of tumor reduction associated with systemic chemotherapy or external beam radiotherapy (EBRT) in the treatment of advanced intraocular retinoblastoma. Methods: Retrospective review of children with Reese-Ellsworth stages IV and V retinoblastoma undergoing primary globe-conserving therapy with either systemic chemoreduction or EBRT. Study variables were recorded at baseline, at monthly intervals for the first 6 months, and at 12 months after the initiation of treatment. Tumor volumes were calculated using basal area and height values determined by ultrasonography, physical examination, and fundus photographic review. Main Outcome Measures: Outcome measures included tumor volume, tumor reduction, regression pattern, treatment-related complications, metastases, and survival. Results: Twenty-six eyes of 26 patients were evaluated for tumor response; 18 patients were treated with systemic chemotherapy and 8 patients were treated with EBRT. Median follow-up was 36 months. A mean 68% reduction in tumor volume occurred after 1 cycle of chemotherapy compared with a 12% reduction at a similar time point (1 month) after initiation of EBRT (P<.004). There was no statistically significant difference in tumor volume reduction between treatment modalities at the 12-month follow-up visit. Both systemic chemoreduction and EBRT achieved 100% globe conservation and 100% patient survival in this series. Conclusions: Retinoblastoma reduction exhibits a differential time course based on the applied primary treatment. Systemic chemotherapy is associated with earlier tumor reduction than EBRT.

UR - http://www.scopus.com/inward/record.url?scp=0037587764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037587764&partnerID=8YFLogxK

U2 - 10.1001/archopht.121.7.979

DO - 10.1001/archopht.121.7.979

M3 - Article

C2 - 12860801

AN - SCOPUS:0037587764

VL - 121

SP - 979

EP - 984

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 7

ER -